Document:

EX-10.37

 Exhibit 10.37 

Execution Version 

ARSANIS, INC. 
 SECOND
AMENDED AND RESTATED 
 STOCKHOLDERS’ AGREEMENT 

Dated as of April 12, 2016 

Amended as of November 3, 2017 

 TABLE OF CONTENTS 

 

					
	 	  	Page No.	 
	 1. VOTING AGREEMENT.
	  	 	2	 
	 1.1 VOTING PROVISIONS REGARDING THE
BOARD OF DIRECTORS
	  	 	2	 
	 1.2 VOTING SHARES
	  	 	3	 
	 1.3 TRANSFERS OF VOTING
RIGHTS
	  	 	3	 
	 1.4 SUCCESSOR DIRECTORS
	  	 	3	 
	 1.5 NO LIABILITY FOR ELECTION
OF RECOMMENDED DIRECTORS
	  	 	4	 
	 1.6 VOTE TO INCREASE AUTHORIZED
COMMON STOCK
	  	 	4	 
		
	 2. DRAG-ALONG RIGHTS.
	  	 	4	 
	 2.1 DEFINITION
	  	 	4	 
	 2.2 ACTIONS TO BE TAKEN
	  	 	4	 
	 2.3 EXCEPTIONS
	  	 	5	 
	 2.4 RESTRICTIONS ON SALES OF
CONTROL OF THE COMPANY
	  	 	7	 
		
	 3. TRANSFER OF SHARES.
	  	 	7	 
	 3.1 RESTRICTIONS ON TRANSFER BY
RESTRICTED STOCKHOLDERS
	  	 	7	 
	 3.2 TRANSFERS BY RESTRICTED
STOCKHOLDERS NOT SUBJECT TO RESTRICTIONS
	  	 	7	 
	 3.3 OFFER OF TRANSFER; NOTICE
OF PROPOSED TRANSFER
	  	 	7	 
	 3.4 COMPANY’S OPTION TO
PURCHASE
	  	 	7	 
	 3.5 INVESTORS’ OPTION TO
PURCHASE
	  	 	8	 
	 3.6 FAILURE TO FULLY EXERCISE
OPTIONS; CO-SALE RIGHTS WITH RESPECT TO SELLING RESTRICTED
STOCKHOLDER
	  	 	9	 
	 3.7 EXCEPTION FOR DRAG-ALONG
RIGHTS
	  	 	10	 
		
	 4. RESTRICTIVE LEGENDS.
	  	 	10	 
	 4.1 VOTING SHARES
	  	 	10	 
	 4.2 TRANSFER RESTRICTION
	  	 	11	 
		
	 5. TERMINATION OF AGREEMENT.
	  	 	11	 
	 5.1 TERMINATION
	  	 	11	 
	 5.2 EXCEPTION
	  	 	11	 
		
	 6. TRANSFER OF RIGHTS
	  	 	11	 
		
	 7. IRREVOCABLE PROXY AND POWER OF ATTORNEY
	  	 	12	 
		
	 8. STAND-OFF AGREEMENT
	  	 	12	 
		
	 9. GENERAL.
	  	 	13	 
	 9.1 ADDITIONAL PARTIES
	  	 	13	 
	 9.2 SEVERABILITY
	  	 	13	 
	 9.3 COVENANTS OF THE
COMPANY
	  	 	13	 
	 9.4 SPECIFIC PERFORMANCE
	  	 	13	 
	 9.5 REMEDIES CUMULATIVE
	  	 	14	 

  
 i 

  

			
	 9.6 GOVERNING LAW
	  	14
	 9.7 NOTICES
	  	14
	 9.8 COMPLETE AGREEMENT; AMENDMENTS
	  	15
	 9.9 CONSTRUCTION
	  	16
	 9.10 COUNTERPARTS; FACSIMILE SIGNATURES
	  	16
	 9.11 AGGREGATION OF SHARES
	  	16

 EXHIBITS 
 Exhibit
A     Schedule of Purchasers 

  
 ii 

 ARSANIS, INC. 

SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

This Second Amended and Restated Stockholders’ Agreement (the “Agreement”) is entered into as of April 12, 2016,
and amended as of November 3, 2017, by and among Arsanis, Inc., a Delaware corporation (the “Company”), the persons and entities listed on Exhibit A attached hereto (collectively with any subsequent
investors or transferees who become parties hereto as Investors pursuant to Section 9.1(a), the “Investors”), and Eszter Nagy, Tillman U. Gerngross and Errik B. Anderson (each, individually, a “Founder” and
collectively, the “Founders,” and collectively with any parties who become parties hereto as Restricted Stockholders pursuant to Section 9.1(b), the “Restricted Stockholders”). The Investors and Restricted
Stockholders are referred to herein collectively as the “Stockholders”). As used in this Agreement, the term “Shares” shall include all shares of capital stock of the Company held by the Stockholders, whether now
owned or hereafter acquired. For purposes of calculating an Investor’s pro rata ownership of Shares, all shares of Series A-1 Convertible Preferred Stock, par value $0.001 per share, of the Company
(the “Series A-1 Preferred Stock”), Series A-2 Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series A-2 Preferred Stock”), Series B Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series B Preferred Stock”) and Series C Convertible Preferred Stock, par value
$0.001 per share, of the Company (the “Series C Preferred Stock” and together with the Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series
B Preferred Stock, the “Preferred Stock”) shall be deemed to have been converted into shares of Common Stock, par value $0.001 per share of the Company (the “Common Stock”). 

Recitals 
 WHEREAS, the
Founders own certain outstanding shares of the Company’s Common Stock; 
 WHEREAS, concurrently with the execution of this Agreement,
the Company and certain of the Investors are entering into a Series C Securities Purchase Agreement (the “Purchase Agreement”) providing for, among other things, the sale of shares of the Company’s Series C Preferred Stock.
Certain of the Investors (the “Existing Investors”) and the Restricted Stockholders are parties to that certain Amended and Restated Stockholders’ Agreement, dated as of July 30, 2013, by and among the Company and the
parties thereto (such agreement, as amended as of February 9, 2015 and further amended as of May 22, 2015, the “Prior Agreement”). 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement in its entirety to provide those Investors
purchasing shares of Series C Preferred Stock with the right, among other rights, to elect certain members of the board of directors of the Company (the “Board”) in accordance with the terms of this Agreement; 

WHEREAS, the Company, the Founders and the Investors wish to (i) protect the management and control of the Company from influence by any
person not acceptable to the Company and the Investors and (ii) assist the Investors in selling their Shares under certain circumstances. 

 NOW, THEREFORE, the parties agree that the provisions of the Prior Agreement are hereby amended
and restated in their entirety, and hereby further agree, as follows: 
 1. Voting Agreement. 

1.1 Voting Provisions Regarding the Board of Directors. In any and all elections of directors of the Company (whether at a meeting or by written
consent in lieu of a meeting), each Stockholder shall vote or cause to be voted all Voting Shares (as defined in Section 1.2 below) owned by him, her or it or over which he, she or it has voting control, and otherwise use his, her or its best
efforts, so as to: 
 (a) fix the number of directors at ten (10); and 

(b) elect as directors: 

(i) Five individuals elected by the holders of a majority of the Preferred Stock voting on an
as-converted to Common Stock basis held by the Investors; provided, that each holder of Preferred Stock (including for purposes of this section, their transferees) agrees to vote all of its
shares of the capital stock of the Company having voting power (and any other shares over which he, she or it exercises voting control), to the extent it holds such voting stock at the relevant time, so that at all times (A) one individual then
designated by Polaris Venture Partners V, L.P. (“Polaris”) so long as Polaris is the holder of any shares of Preferred Stock, the first such designee being Terrance McGuire, (B) one individual then designated by OrbiMed Private
Investments IV, LP (“OrbiMed”) so long as OrbiMed is the holder of any shares of Preferred Stock, the first such designee being Carl Gordon, (C) one individual then designated by SV Life Sciences Fund V, L.P.
(“SVLS”) so long as SVLS is the holder of any shares of Preferred Stock, the first such designee being Michael Ross, and (D) one individual then designated by NeoMed Innovation V L.P. (“NeoMed”) so long as
NeoMed is the holder of any shares of Preferred Stock, the first such designee being Claudio Nessi, are members of the Board of Directors of the Company, provided, however, that should any of Polaris, OrbiMed, SVLS or NeoMed, or their
respective affiliates, cease to hold any shares of Preferred Stock, then such party shall immediately lose its right to designate a director and from that point forward, such director shall be nominated and elected by the holders of a majority of
the shares of Preferred Stock held by the Investors, voting on an as-converted to Common Stock basis; 

(ii) One individual designated by Tillman Gerngross so long as he is the holder of any shares of Common Stock, such designee to
initially be Tillman Gerngross; 
 (iii) One individual designated by the Founders holding a majority of the aggregate Shares
held by the Founders; 

  
 - 2 - 

 (iv) The Company’s most senior executive officer who is an employee of the
Company, as determined by the Board of Directors, currently Eszter Nagy; and 
 (v) Two individuals designated by a majority
of the members of the Board, such designees to initially be Dan Burgess and Amy Schulman. 
 1.2 Voting Shares. “Voting Shares”
shall mean the Shares and any and all other shares of capital stock of the Company, by whatever name called, which carry voting rights (including voting rights which arise by reason of default) which are now owned or subsequently acquired by a
Stockholder, however acquired, including, without limitation, through stock splits, stock dividends, reclassifications, recapitalizations and other similar events. 

1.3 Transfers of Voting Rights. Any transferee to whom Voting Shares are transferred by a Stockholder, whether voluntarily or by operation of
law, shall be bound by the obligations imposed upon the transferor under this Agreement, to the same extent as if such transferee were a Stockholder hereunder, and, as a condition precedent to the Company’s recognizing such transfer, each
transferee or assignee shall agree in writing to be subject to each of the terms of this Agreement by executing and delivering an Adoption Agreement substantially in the form attached hereto as Exhibit B. Upon the execution and delivery of an
Adoption Agreement by any transferee, such transferee shall be deemed to be a party hereto as if such transferee were the transferor and such transferee’s signature appeared on the signature pages of this Agreement and shall be deemed to be an
Investor and Stockholder, or Restricted Stockholder and Stockholder, as applicable. The Company shall not permit the transfer of the Voting Shares subject to this Agreement on its books or issue a new certificate representing any such Voting Shares
unless and until such transferee shall have complied with the terms of this Section 1.3. Each certificate representing Voting Shares subject to this Agreement if issued on or after the date of this Agreement shall be endorsed by the Company
with the legends set forth in Section 4. 
 1.4 Successor Directors. If a person who has been elected as a director pursuant to a designation
under Section 1.1(b)(i), 1.1(b)(ii) or 1.1(b)(iii) above shall cease to serve as a director for any reason, the persons or entities who had the right to designate such person as a director under Section 1.1(b)(i), 1.1(b)(ii) or 1.1(b)(iii)
above (the “Nominating Party”), shall have the right to designate a successor nominee and each of the other parties hereto who or which are entitled under the Company’s Certificate of Incorporation to vote or act by written
consent with respect to the election of such successor nominee as a director shall vote or cause to be voted, or execute or cause to be executed a written consent with respect to, all Voting Shares in favor of such successor nominee. If a person who
has been elected as a director under Section 1.1(b)(iv) above shall cease to serve as a director for any reason, the Board of Directors shall promptly designate the Company’s most senior executive officer who is an employee of the Company
as a successor nominee and each of the other parties hereto who or which are entitled under the Company’s Certificate of Incorporation to vote or act by written consent with respect to the election of such successor nominee as a director shall
vote or cause to be voted, or execute or cause to be executed a written consent with respect to, all Voting Shares in favor of such successor nominee. If a person who has been elected as a director under Section 1.1(b)(v) above shall cease to
serve as a director for any reason, the Board of Directors shall promptly designate a successor nominee and each of the other parties hereto who or which are entitled under the Company’s Certificate of 

  
 - 3 - 

 Incorporation to vote or act by written consent with respect to the election of such successor nominee as a
director shall vote or cause to be voted, or execute or cause to be executed a written consent with respect to, all Voting Shares in favor of such successor nominee. Except as provided herein, a director designated under Section 1.1(b)(i),
1.1(b)(ii), 1.1(b)(iii) or 1.1(b)(v) above may be removed during his or her term of office, with or without cause, by and only by the affirmative vote or written consent of those Nominating Parties that had the right to designate the director (or
the Board of Directors in the case of a director nominated under Section 1.1(b)(v)). A director designated under Section 1.1(b)(iv) shall not be removed so long as such director remains (a) the Company’s most senior executive
officer and (b) an employee of the Company. If a Nominating Party (or the Board of Directors in the case of a director nominated under Section 1.1(b)(v)) notifies the other parties hereto that it desires to remove its nominee as a
director, each of the other parties hereto who or which are entitled under the Certificate of Incorporation to vote or act by written consent with respect to the removal of such nominee as a director, shall vote or cause to be voted, or execute or
cause to be executed a written consent with respect to, all Voting Shares in favor of such removal. If a Nominating Party (or the Board of Directors in the case of a director nominated under Section 1.1(b)(v)) notifies the Company that it
desires to remove its nominee as a director and/or designate a successor nominee by means of stockholder vote, the Company shall, at the request of such Nominating Party or the Board of Directors, as applicable, use its reasonable best efforts to
ensure that a meeting of stockholders of the Company is promptly called for such purpose. 
 1.5 No Liability for Election of Recommended Directors.
No Stockholder, nor any affiliate of any Stockholder, shall have any liability as a result of designating a person for election as a director for any act or omission by such designated person in his or her capacity as a director of the Company, nor
shall any Stockholder have any liability as a result of voting for any such designee in accordance with the provisions of this Agreement. 
 1.6 Vote to
Increase Authorized Common Stock. Each Stockholder agrees to vote or cause to be voted all Voting Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as
shall be necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common Stock available for conversion of all of the shares of Preferred Stock outstanding at any given
time. 
 2. Drag-Along Rights. 
 2.1
Definition . A “Sale of the Company” shall mean a transaction that qualifies as an “Event” pursuant to the Company’s Certificate of Incorporation. 

2.2 Actions to be Taken. In the event that the holders of at least a majority of the shares of Common Stock then issuable upon conversion of the shares
of the then-outstanding Preferred Stock (the “Selling Investors”) approve a Sale of the Company in writing, specifying that this Section 2 shall apply to such transaction, then each Stockholder hereby agrees: 

(a) if such transaction requires stockholder approval, with respect to all Voting Shares and/or any other Company securities
that such Stockholder owns or over which such Stockholder otherwise exercises voting power, (i) to vote (in person, by 

  
 - 4 - 

 
proxy or by action by written consent, as applicable) all Voting Shares in favor of, and adopt, such Sale of the Company and to vote in opposition to any and all other proposals that could
reasonably be expected to delay or impair the ability of the Company to consummate such Sale of the Company, and (ii) to be present, in person or by proxy, as a holder of Voting Shares or other securities of the Company, at any related
stockholder meetings that have been duly noticed and held, and be counted for the purposes of determining the presence of a quorum at such meetings; 

(b) if such transaction is a sale of stock by Selling Investors, to sell the same proportion of shares of capital stock of the
Company beneficially held by such Stockholder as is being sold by the Selling Investors to the person to whom the Selling Investors propose to sell their Shares, and on the same terms and conditions as the Selling Investors; 

(c) to execute and deliver all related documentation and take such other action in support of the Sale of the Company as shall
reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 2, including without limitation executing and delivering instruments of conveyance and transfer, and any purchase
agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), and any similar or related
documents; 
 (d) not to deposit, and to cause their affiliates not to deposit, except as provided in this Agreement, any
voting securities of the Company owned by such party or affiliate in a voting trust or subject any such voting securities to any arrangement or agreement with respect to the voting of such shares of capital stock, unless specifically requested to do
so by the acquirer, the Company or the Selling Investors in connection with the Sale of the Company; and 
 (e) to refrain
from exercising any dissenters’ rights or rights of appraisal under applicable law at any time with respect to such Sale of the Company. 
 2.3
Exceptions. Notwithstanding the forgoing, a Stockholder will not be required to comply with Section 2.2 above in connection with any specific Sale of the Company (the “Proposed Sale”) unless: 

(a) any representations and warranties to be made by such Stockholder in connection with the Proposed Sale are limited to
representations and warranties related to authority, ownership of the Shares held by such Stockholder and the ability to convey title to such Shares, including but not limited to representations and warranties that (i) the Stockholder holds all
right, title and interest in and to the Company’s securities such Stockholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Stockholder in connection with the transaction have been duly
authorized, if applicable, (iii) the documents to be entered into by the Stockholder have been duly executed and delivered to the acquirer and are enforceable against the Stockholder in accordance with their respective terms and
(iv) neither the execution and 

  
 - 5 - 

 
delivery of documents to be entered into in connection with the transaction, nor the performance of the Stockholder’s obligations thereunder, will cause a breach or violation of the terms of
any agreement, law or judgment, order or decree of any court or governmental agency; 
 (b) the liability for
indemnification, if any, of such Stockholder in the Proposed Sale, and with respect to any representation or warranty made by the Company in connection with such Proposed Sale, is several and not joint with any other person, and is pro rata in
accordance with such Stockholder’s relative stock ownership of the Company; 
 (c) such liability shall be limited to
the amount of consideration actually paid to such Stockholder in connection with such Proposed Sale, except with respect to (i) representations and warranties of such Stockholder related to authority, ownership of the Shares held by such
Stockholder and the ability to convey title to such Shares, (ii) any covenants made by such Stockholder with respect to confidentiality or voting related to the Proposed Sale or (iii) claims related to fraud or willful breach by such
Stockholder, the liability for which need not be limited; 
 (d) upon the consummation of the Proposed Sale, each holder of
each series of the Company’s Preferred Stock and each holder of Common Stock will receive the same form and amount of consideration per share of such series of Preferred Stock or Common Stock, respectively, and the holders of each series of
Preferred Stock and Common Stock shall, together, receive the same form and amount of consideration per share of such stock, taking into account the relative liquidation preference to which the holders of each respective series of Preferred Stock
and the holders of Common Stock are entitled in a liquidation (if applicable) in accordance with the Company’s Certificate of Incorporation in effect immediately prior to the Proposed Sale, provided, however that if the consideration to be paid
in exchange for the Shares pursuant to the Proposed Sale includes any securities and due receipt thereof by any Stockholder would require under applicable law (x) the registration or qualification of such securities or of any person as a broker
or dealer or agent with respect to such securities or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors”
as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Stockholder,
an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such securities in exchange for the Shares; and 

(e) if any holders of any series of Preferred Stock or of Common Stock are given an option as to the form and amount of
consideration to be received as a result of the Proposed Sale, all holders of such respective series of Preferred Stock or of Common Stock will be given the same option. 

  
 - 6 - 

 2.4 Restrictions on Sales of Control of the Company. No Stockholder shall be a party to any sale or
transfer, or series of related sales or transfers, of Voting Shares representing fifty percent (50%) or more of the then-outstanding voting power of the Company to any person or entity, or group of related persons or entities (a “Stock
Sale”), unless all holders of Preferred Stock are allowed to participate in such transaction and the consideration received pursuant to such transaction is allocated among the parties thereto in the manner specified in the Company’s
Certificate of Incorporation in effect immediately prior to the Stock Sale (as if such transaction were an Event pursuant to the Company’s Certificate of Incorporation), unless the holders of at least a majority of the then-outstanding shares
of Preferred Stock voting as a single class on an as-converted to Common Stock basis elect otherwise by written notice given to the Company at least ten (10) days prior to the effective date of any such
transaction or series of related transactions. 
 3. Transfer of Shares. 

3.1 Restrictions on Transfer By Restricted Stockholders. Any sale, assignment, transfer or other disposition, whether voluntarily or by operation of
law (collectively, “Transfer”), of any Shares by a Restricted Stockholder other than according to the terms of this Agreement, shall be void and shall transfer no right, title, or interest in or to any of such Shares to the
purported transferee. 
 3.2 Transfers By Restricted Stockholders Not Subject to Restrictions. A Restricted Stockholder may Transfer without
compliance with the provisions of Sections 3.3 through 3.6 hereof (i) any or all of his Shares to his spouse, lineal ancestors or descendants (including adopted children and grandchildren) (collectively, “Family Members”)
or to a trust established for the benefit of any of his Family Members, (ii) any or all of his Shares under his will or otherwise pursuant to the laws of descent and distribution, (iii) any or all of his Shares to a partnership, limited
liability company or other entity controlled by such Restricted Stockholder, the partners or members of which consist solely of such Restricted Stockholder, his spouse and/or any of his other Family Members, or (iv) to a charitable organization
or educational institution qualifying for exemption from Federal income taxes pursuant to Section 501(c)(3) of the Internal Revenue Code, provided in the case of each such Transfer that the transferee delivers a written instrument to the other
parties hereto agreeing to be bound by the terms hereof as if he, she or it were a Restricted Stockholder and, in the case of Transfer from a Founder, a Founder. 

3.3 Offer of Transfer; Notice of Proposed Transfer. If a Restricted Stockholder desires to Transfer any of his Shares, or any interest in such Shares,
in any transaction other than pursuant to Section 3.2 of this Agreement, such Restricted Stockholder (a “Selling Restricted Stockholder”) shall first deliver written notice of his desire to do so (the
“Seller’s Notice”) to the Company and each Investor in the manner prescribed in Section 9.7 of this Agreement. The Seller’s Notice must specify (i) the name and address of the party to which
the Selling Restricted Stockholder proposes to Transfer the Shares or an interest in the Shares (the “Offeror”), (ii) the number of Shares the Selling Restricted Stockholder proposes to Transfer (the “Offered
Shares”), (iii) the consideration per Offered Share to be delivered to the Selling Restricted Stockholder (if applicable) for the proposed Transfer, and (iv) all other material terms and conditions of the proposed transaction.

 3.4 Company’s Option to Purchase. 

  
 - 7 - 

 (a) The Company shall have the first option to purchase all or any part of the
Offered Shares of a Selling Restricted Stockholder for the consideration per share and on the terms and conditions no less favorable than those specified in the Seller’s Notice. The Company must exercise such option no later than 15 days after
such Seller’s Notice is deemed under Section 9.7 hereof to have been delivered to it by giving written notice to the Selling Restricted Stockholder. 

(b) In the event the Company does not exercise its option within such 15-day period
with respect to all or part of the Offered Shares of a Selling Restricted Stockholder, the Secretary of the Company shall, by the last day of such period, give written notice of that fact to each Investor (the “Investor Notice”).
The Investor Notice shall specify the number of Offered Shares of a Selling Restricted Stockholder not purchased by the Company (the “Remaining Shares”). 

(c) In the event the Company duly exercises its option to purchase all or part of the Offered Shares of a Selling Restricted
Stockholder, the closing of such purchase shall take place at the offices of the Company on the later of (i) the date that is five days after the expiration of such 15-day period or (ii) the date
that the Investors consummate their purchases of Offered Shares under Section 3.5 hereof. 
 (d) To the extent that the
consideration proposed to be paid by the Offeror for the Offered Shares consists of property other than cash or a promissory note, the consideration required to be paid by the Company and/or the Investors when exercising their options under
Sections 3.4 and 3.5 hereof may consist of cash equal to the value of such property, as determined in good faith by agreement of the Selling Restricted Stockholder, the Company and/or the Investors acquiring such Offered Shares. 

(e) Notwithstanding anything to the contrary in this Agreement, neither the Company nor the Investors shall have any right to
purchase any of the Offered Shares hereunder unless the Company and/or the Investors exercise their option or options to purchase all of the Offered Shares. 

3.5 Investors’ Option to Purchase. 

(a) Each Investor shall have an option, exercisable for a period of 15 days from the date of delivery of the Investor Notice,
to purchase its pro rata share of the Remaining Shares for the consideration per share and on terms and conditions no less favorable than those set forth in the Seller’s Notice. Such option shall be exercised by delivery of written notice to
the Secretary of the Company. Alternatively, each Investor may within the same 15-day period notify the Secretary of the Company and the Selling Restricted Stockholder in writing of its desire to participate
in the sale of the Shares pursuant to Section 3.6 on the terms set forth in the Seller’s Notice and the number of Shares it proposes to sell. 

(b) In the event options to purchase have been exercised by the Investors with respect to some but not all of the Remaining
Shares, those Investors who have exercised their options within the 15-day period specified in Section 3.5(a) shall have an additional 

  
 - 8 - 

 
option, for a period of five (5) days next succeeding the expiration of such 15-day period, to purchase all or any part of the balance of such
Remaining Shares on terms and conditions no less favorable than those set forth in the Seller’s Notice, which option shall be exercised by the delivery of written notice to the Secretary of the Company. In the event there are two or more such
Investors that choose to exercise the last-mentioned option for a total number of Shares in excess of the number available, the Shares available for each such Investor’s option shall be allocated to such Investor pro rata based on the number of
shares of Preferred Stock calculated on an as-converted to Common Stock basis owned by the Investors so electing. 

(c) If the options to purchase the Remaining Shares are exercised in full by the Investors, the Secretary of the Company shall
promptly notify all of the exercising Investors of that fact. The closing of the purchase of the Remaining Shares shall take place at the offices of the Company no later than five days after the date of such notice to the Investors. 

(d) Any Shares sold by a Selling Restricted Stockholder in compliance with the provisions of Sections 3.3 through 3.6 of
this Agreement shall be transferred free and clear of the covenants, agreements and restrictions set forth in Section 3 of this Agreement, provided, that, the transferee and any subsequent transferee of the Shares shall hold the
Shares so acquired subject to all other covenants, agreements and restrictions imposed by this Agreement and shall be deemed a party to this Agreement for all other purposes. As a condition to any such Transfer, (i) the transferor shall notify
the Company and the other Stockholders thereof, which notice shall include a brief description of such Transfer and (ii) each transferee shall execute and deliver a written instrument agreeing to be bound by the provisions of this Agreement
(other than the provisions of this Section 3). 
 3.6 Failure to Fully Exercise Options; Co-Sale Rights with
Respect to Selling Restricted Stockholder. 
 (a) If the Company and the Investors do not exercise their options to
purchase all of the Offered Shares within the periods described in this Agreement (the “Option Period”), then all options of the Company and the Investors to purchase the Offered Shares, whether exercised or not, shall terminate;
but each Investor who has, pursuant to Section 3.5(a), expressed a desire to sell Shares in the transaction (“Participating Investors”) shall be entitled to do so pursuant to this Section. The Secretary of the Company shall
promptly, upon expiration of the Option Period, notify the Selling Restricted Stockholder of the aggregate number of Shares the Participating Investors wish to sell. The Selling Restricted Stockholder shall use his best efforts to interest the
Offeror in purchasing, in addition to the Offered Shares, the Shares the Participating Investors wish to sell. If the Offeror does not wish to purchase all of the Shares made available by the Selling Restricted Stockholder and the Participating
Investors, then each Participating Investor and the Selling Restricted Stockholder shall be entitled to sell, at the price and on terms and conditions no less favorable than those set forth in the Seller’s Notice, a portion of the Shares being
sold to the Offeror, in the same proportion as their respective ownership of Shares calculated on an as-converted to Common Stock 

  
 - 9 - 

 
basis bears to the aggregate number of Shares calculated on an as-converted to Common Stock basis owned by the Selling Restricted Stockholder and the
Participating Investors. The transaction contemplated by the Seller’s Notice shall be consummated no later than 60 days after the expiration of the Option Period. 

(b) The Selling Restricted Stockholder shall be entitled to sell to the Offeror, according to the terms set forth in the
Seller’s Notice, that number of Offered Shares which equals the difference between the number of Offered Shares desired to be purchased by the Offeror and (if applicable) the number of Shares the Participating Investors are entitled to sell in
accordance with the provisions of this Section 3.6. If the Selling Restricted Stockholder wishes to Transfer any such Offered Shares at a price per Offered Share which differs from that set forth in the Seller’s Notice, upon terms that
differ in any material respect from those previously offered to the Company and the Investors, or more than 60 days after the expiration of the Option Period, then, as a condition precedent to such transaction, such Offered Shares must first be
offered to the Company and the Investors (if applicable) on terms and conditions no less favorable than those given the Offeror, and in accordance with the procedures and time periods set forth above. 

(c) The proceeds of any sale made by a Selling Restricted Stockholder without compliance with the provisions of this
Section 3.6 shall be deemed to be held in constructive trust in such amount as would have been due the Participating Investors if the Selling Restricted Stockholder had complied with this Agreement. The contents of any such trust shall be
delivered to the Participating Investors upon surrender of the applicable Shares to the Selling Restricted Stockholder. 
 3.7 Exception for Drag-Along
Rights. This Section 3 shall not apply to any sale by a Restricted Stockholder pursuant to a Sale of the Company that the Selling Investors (i) have approved and (ii) with respect to which the Selling Investors have specified in
writing that Section 2 of this Agreement shall apply. 
 4. Restrictive Legends. 

4.1 Voting Shares. All certificates representing Voting Shares owned or hereafter acquired by the Stockholders or any transferee bound by this
Agreement shall have affixed thereto a legend substantially in the following form: 
 The shares of stock represented by this certificate are
subject to certain agreements as set forth in a Stockholders’ Agreement, as may be amended from time to time, by and among the registered owner of this certificate, the Company and certain other stockholders of the Company, a copy of which is
available for inspection by a prospective investor without charge at the office of the Secretary of the Company. 
 Each Restricted Stockholder agrees to
present the certificates representing Voting Shares owned or hereafter acquired by him to the Secretary of the Company and cause the Secretary to stamp on the certificate in a prominent manner such a legend. 

  
 - 10 - 

 4.2 Transfer Restriction. Each Restricted Stockholder agrees to present the certificates representing the
Shares presently owned or hereafter acquired by him to the Secretary of the Company and cause the Secretary to stamp on the certificate in a prominent manner the following legend: 

The sale or other disposition of any of the shares represented by this certificate is restricted by a Stockholders’ Agreement, as may be
amended from time to time, among certain of the shareholders of this Company and this Company, a copy of which is available for inspection by a prospective purchaser without charge at the office of the Secretary of the Company. 

5. Termination of Agreement. 
 5.1
Termination. This Agreement shall terminate upon the earlier to occur of the following events: 
 (a) the consummation
of a Sale of the Company, including the distribution of the net proceeds of such Sale of the Company in accordance with the Company’s Certificate of Incorporation, provided that the provisions of Section 2 hereof will
continue after the closing of any Sale of the Company to the extent necessary to enforce the provisions of Section 2 with respect to such Sale of the Company; 

(b) the closing of a Qualified IPO (as defined in the Company’s Certificate of Incorporation, as it may be amended and/or
restated from time to time); 
 (c) the redemption or conversion of all shares of Preferred Stock; or 

(d) upon vote of the parties hereto pursuant to Section 9.8(b) hereof. 

5.2 Exception. The provisions of Sections 3.3 through 3.6, inclusive, of this Agreement shall not apply to sales of Shares pursuant to a
transaction referred to in Section 5.1 above. 
 6. Transfer of Rights. This Agreement, and the rights and obligations of each
Investor hereunder, may be assigned by such Investor (a) to any person or entity to which such Investor transfers a number of shares of Preferred Stock equal to not less than five percent (5%) of the total number of shares of Preferred Stock
held by such Investor (subject to adjustment for any stock dividend, stock split, stock split-up, combination or shares or the like) immediately following the Closing (as defined in the Purchase Agreement),
(b) if the Investor is an individual, to any family member or trust or partnership established for such family member, or (c) if the Investor is a corporation, partnership, limited liability company or other entity, to any current or
former partner (including general partner and limited partner), shareholder, member or other 

  
 - 11 - 

 
affiliate of the Investor. Such transferee shall be deemed an “Investor” for purposes of this Agreement, provided that the transferee provides written notice of such assignment to the
Company and agrees in writing to be bound by the terms and conditions set forth herein as if he, she or it were the original Investor. 
 7.
Irrevocable Proxy and Power of Attorney. Each party to this Agreement hereby constitutes and appoints as the proxies of the party and hereby grants a power of attorney to the President of the Company, and a designee of the Investors, and
each of them, with full power of substitution, with respect to the matters set forth herein, including without limitation, election of persons as members of the Board in accordance with Sections 1.1 and 1.4 hereto, votes to increase authorized
shares pursuant to Section 1.6 hereof and votes regarding any Sale of the Company pursuant to Section 2 hereof, and hereby authorizes each of them to represent and to vote, if and only if the party (i) fails to vote or
(ii) attempts to vote (whether by proxy, in person or by written consent), in a manner which is inconsistent with the terms of this Agreement, all of such party’s Shares in favor of the election of persons as members of the Board
determined pursuant to and in accordance with the terms and provisions of this Agreement or the increase of authorized shares or approval of any Sale of the Company pursuant to and in accordance with the terms and provisions of Sections 1.1, 1.4,
1.6 and 2, respectively, of this Agreement or to take any action necessary to effect Sections 1.1, 1.4, 1.6 and 2, respectively, of this Agreement. Each of the proxy and power of attorney granted pursuant to the immediately preceding sentence is
given in consideration of the agreements and covenants of the Company and the parties in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be irrevocable unless and until this
Agreement terminates or expires pursuant to Section 5 hereof. Each party hereto hereby revokes any and all previous proxies or powers of attorney with respect to the Shares and shall not hereafter, unless and until this Agreement terminates or
expires pursuant to Section 5 hereof, purport to grant any other proxy or power of attorney with respect to any of the Shares, deposit any of the Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement or
understanding with any person, directly or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the Shares, in each case, with respect to any of the matters set forth herein. 

8. Stand-Off Agreement. Each Stockholder, if requested by the Company and the managing
underwriter of an offering by the Company of Common Stock or other securities of the Company pursuant to a registration statement, shall agree not to sell publicly or otherwise transfer or dispose of any Shares held by such Stockholder for a
specified period of time (not to exceed 180 days, which period may be extended upon the request of the managing underwriter for a period of up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release
within fifteen (15) days of the expiration of the 180-day lockup period) following the effective date of such Registration Statement; provided, that: 

(a) any discretionary modification, waiver or termination of the restrictions of such agreements (including this Agreement) by
the Company or the managing underwriter shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of shares held by each subject to such agreements; 

  
 - 12 - 

 (b) such agreement shall only apply to the Company’s first registration
statement covering Shares to be sold by or on behalf of the Company to the public in an underwritten offering; and 
 (c)
such agreement shall not apply to securities acquired in an open market transaction after such registration statement is declared effective. 

9. General. 
 9.1 Additional
Parties. 
 (a) Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
Preferred Stock after the date hereof, as a condition to the issuance of such shares the Company shall require that any purchaser become a party to this Agreement by executing and delivering (i) the Adoption Agreement attached to this Agreement
as Exhibit B, or (ii) a counterpart signature page hereto agreeing to be bound by and subject to the terms of this Agreement as an Investor and Stockholder hereunder. In either event, each such person shall thereafter shall be deemed an
Investor and Stockholder for all purposes under this Agreement. 
 (b) In the event that after the date of this Agreement,
the Company enters into an agreement with any person or entity to issue shares of capital stock to such person or entity (other than to a purchaser of Preferred Stock described in Section 9.1(a) above), then, the Company shall cause such person
or entity, as a condition precedent to entering into such agreement, to become a party to this Agreement by executing an Adoption Agreement in the form attached hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement
as a Restricted Stockholder and a Stockholder and thereafter such person shall be deemed a Restricted Stockholder and a Stockholder for all purposes under this Agreement. Further, following the date of this Agreement, the Company will use
commercially reasonable efforts to cause each existing holder of shares of the capital stock of the Company that are not otherwise a party to this Agreement to become a party to this Agreement by executing an Adoption Agreement in the form attached
hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement as a Restricted Stockholder and a Stockholder. 
 9.2
Severability. The provisions of this Agreement are severable, so that the invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other term or provision of this Agreement,
which shall remain in full force and effect. 
 9.3 Covenants of the Company. The Company agrees to use its commercially reasonable efforts, within
the requirements of applicable law, to ensure that the rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement. Such actions include, without limitation, the use of the Company’s commercially
reasonable efforts to cause the nomination and election of the directors as provided in this Agreement. 
 9.4 Specific Performance. In addition to
any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company, the Restricted Stockholders and the other
Investors hereunder and to such other injunctive or other equitable relief as may be granted by a court of competent jurisdiction. 

  
 - 13 - 

 9.5 Remedies Cumulative. All remedies, either under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative. 
 9.6 Governing Law. 

(a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (without reference
to the conflicts of law provisions thereof). Subject to Subsection 9.6(b), the parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Massachusetts and to the jurisdiction of the United States
District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (ii) agree not to commence any suit, action or other proceeding arising out of or based upon
this Agreement except in the state courts of Massachusetts or the United States District Court for the District of Massachusetts, and (iii) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit,
action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient
forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

(b) Notwithstanding the foregoing Subsection 9.6(a), in the event there is a suit, action or other proceeding of the type
described in Article Eleventh of the Company’s Amended and Restated Certificate of Incorporation (i) pending in the Court of Chancery in the State of Delaware or (ii) to be filed simultaneously with the Court of Chancery in the State
of Delaware, in either case with respect to facts related to any suit, action or proceeding under this Agreement, then any suit, action or other proceeding under this Agreement must be brought exclusively in the Court of Chancery in the State of
Delaware and the parties (x) hereby irrevocably and unconditionally submit to the jurisdiction of the Court of Chancery in the State of Delaware and (y) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise,
in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in
an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

9.7 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours,
then on the recipient’s next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business day after deposit with a nationally recognized
overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt: 

  
 - 14 - 

 (a) If to the Company, or a Restricted Stockholder, at 890 Winter Street, Suite
230, Waltham, Massachusetts 02451, Attn: Michael Gray, or at such other address or addresses as may have been furnished in writing by the Company to the Investors, with a copy to Foley Hoag LLP, 155 Seaport Boulevard, Boston, Massachusetts 02210,
Attention: Robert L. Birnbaum, Esq. 
 (b) If to an Investor, at the address set forth on Exhibit A
attached hereto. 
 9.8 Complete Agreement; Amendments. 

(a) This Agreement constitutes the full and complete agreement of the parties hereto with respect to the subject matter hereof
and amends and restates in its entirety the Prior Agreement. 
 (b) No amendment, modification or termination of any
provision of this Agreement shall be valid unless in writing and signed by (i) the Company and (ii) the Stockholders holding at least a majority of the Shares held by all Stockholders voting on an
as-converted to Common Stock basis. Notwithstanding the foregoing, (i) Section 1.1(b)(i)(A) of this Agreement regarding Polaris’ right to designate a director may not be amended, terminated or
waived without the written consent of Polaris so long as Polaris has the right to designate a director, (ii) Section 1.1(b)(i)(B) of this Agreement regarding OrbiMed’s right to designate a director may not be amended, terminated or
waived without the written consent of OrbiMed so long as OrbiMed has the right to designate a director, (iii) Section 1.1(b)(i)(C) of this Agreement regarding SVLS’ right to designate a director may not be amended, terminated or
waived without the written consent of SVLS so long as SVLS has the right to designate a director, (iv) Section 1.1(b)(i)(D) of this Agreement regarding NeoMed’s right to designate a director may not be amended, terminated or waived
without the written consent of NeoMed so long as NeoMed has the right to designate a director, (v) Section 1.1(b)(ii) many not be amended, terminated or waived without the written consent of Tillman Gerngross so long as Tillman Gerngross
has the right to designate a director and (vi) Section 1.1(b)(iii) may not be amended, terminated or waived without the written consent of the Founders holding a majority of the aggregate Shares held by the Founders so long as such
Founders have the right to designate a director. The applicability of any provisions of this Agreement in a particular instance may be waived by the party entitled to the benefit of such provision(s) as follows: in the case of the Company, by
written instrument signed on behalf of the Company by a duly authorized officer; in the case of the Founders, by written instrument signed on behalf of the Founders holding at least a majority of the shares of Common Stock held by all Founders; in
the case of the Restricted Stockholders, by written instrument signed on behalf of the Restricted Stockholders holding at least a majority of the shares of Common Stock held by the Restricted Stockholders; and in the case of the Investors, by a
written instrument signed by the Investors holding at least a majority of the shares of 

  
 - 15 - 

 
Preferred Stock voting on an as-converted to Common Stock basis. No waivers of or exceptions to any term, condition or provision of this Agreement, in any
one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. Any such amendment or waiver effected in accordance with this Section 9.8(b) shall be binding on all parties
hereto, even if they did not consent to such amendment or waiver. 
 9.9 Construction. A reference to a Section or Exhibit shall mean a Section in,
or Exhibit to, this Agreement unless otherwise expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement which shall be considered as a whole. The words
“include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” Whenever the context may require, any pronouns used herein shall include
the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 
 9.10
Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one Agreement binding on all the parties hereto.
This Agreement may be executed by facsimile signatures. 
 9.11 Aggregation of Shares. All shares of capital stock of the Company held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

[Remainder of page intentionally left blank.] 

  
 - 16 - 

 IN WITNESS WHEREOF, this Second Amended and Restated Stockholders’ Agreement has been
executed under seal as of the date first above written. 
  

			
	COMPANY:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Tillman U. Gerngross

		 	Name: Tillman U. Gerngross
		 	Title:   President

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 
	
	 FOUNDERS:
  

/s/ Eszter Nagy

	 Eszter Nagy
  

/s/ Tillman U. Gerngross

	 Tillman U. Gerngross
  

/s/ Errik B. Anderson

	Errik B. Anderson

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 
	
	 RESTRICTED STOCKHOLDERS:
  

/s/ Gabor Nagy                April 9, 2016

	 Gabor Nagy
  

/s/ Zoltan Magyarics                 2016-APR-09

	Zoltan Magyarics 

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 
							
	INVESTORS:
	
	ORBIMED PRIVATE INVESTMENTS IV LP
		
	By:	 	OrbiMed Capital GP IV LLC
		 	Its General Partner
		
	By:	 	OrbiMed Advisors LLC,
		 	Its Managing Member

 
					
			
		 	By:	 	 /s/ Carl L. Gordon

		 		 	Name: Carl L. Gordon
		 		 	Title: Member

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 
							
	INVESTORS:
	
	POLARIS VENTURE PARTNERS V, L.P.
		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner

 
					
			
		 	By:	 	 /s/ William E. Bilodeau

		 		 	Name: William E. Bilodeau
		 		 	Title: Attorney-in-fact

  

							
	 POLARIS VENTURE PARTNERS

ENTREPRENEURS’ FUND V, L.P.

		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner
			
		 	By:	 	 /s/ William E. Bilodeau

		 		 	Name: William E. Bilodeau
		 		 	Title: Attorney-in-fact

  

							
	 POLARIS VENTURE PARTNERS FOUNDERS’

FUND, V, L.P.

		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner
			
		 	By:	 	 /s/ William E. Bilodeau

		 		 	Name: William E. Bilodeau
		 		 	Title: Attorney-in-fact

  

							
	 POLARIS VENTURE PARTNERS SPECIAL

FOUNDERS’ FUND V, L.P.

		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner
			
		 	By:	 	 /s/ William E. Bilodeau

		 		 	Name: William E. Bilodeau
		 		 	Title: Attorney-in-fact

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 
					
	INVESTORS:
	
	SV LIFE SCIENCES FUND V, L.P.
		
	By:	 	SV Life Sciences Fund V (GP), L.P.,
		 	Its sole General Partner
		
	By:	 	SVLSF V, LLC,
		 	Its sole General Partner
			
		 	By:	 	 /s/ Denise W. Marks

		 		 	Name: Denise W. Marks
		 		 	Title: SVLSF V, LLC, Member

  

					
	 SV LIFE SCIENCES FUND V STRATEGIC

PARTNERS, L.P.

		
	By:	 	SV Life Sciences Fund V (GP), L.P.,
		 	Its sole General Partner
		
	By:	 	SVLSF V, LLC,
		 	Its sole General Partner
			
		 	By:	 	 /s/ Denise W. Marks

		 		 	Name: Denise W. Marks
		 		 	Title: SVLSF V, LLC, Member

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 
					
	INVESTORS:
	
	NEOMED INNOVATION V L.P.
			
	By:	 	/s/ PETER CANHAM	 	/s/ TAMARA WILLIAMS
		 	Name: PETER CANHAM	 	TAMARA WILLIAMS
		 	Title: ALTERNATE DIRECTOR        	 	DIRECTOR

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

			
	INVESTORS:
	
	EMBL TECHNOLOGY FUND II GMBH & CO. KG
		
	By:	 	EMBL VENTURES VERWALTUNGS GMBH,
		 	its General Partner

  

			
	By:	 	/s/ Jan Adams
		 	  
 Name: Jan Adams

		 	Title:   Executive Director

  

			
	By:	 	/s/ Stefan Herr
		 	  
 Name: Stefan Herr

		 	Title:   Executive Director

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

			
	INVESTORS:
	
	Anna-Maria and Stephen Kellen Foundation, Inc.
		
	By:	 	/s/ Michael M. Kellen
	Name:	 	  
 Michael M. Kellen

	Title:	 	President

  
 Signature Page to
Second Amended and Restated Stockholders Agreement 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms of
that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	 ALEXANDRIA VENTURE INVESTMENTS, LLC,

a Delaware limited liability company

		
	By:    	 	ALEXANDRIA REAL ESTATE EQUITIES, INC.,
		 	a Maryland corporation, managing member
		
	By:    	 	 /s/ Aaron Jacobson

		 	 Name: Aaron Jacobson
 Title: VP - Corporation
Counsel

		
	Address:	 	     385 E. Colorado Blvd., Suite 299

    Pasadena, CA 91101

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

	Name:	 	Rene Russo
	Title:	 	President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms of
that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	GV 2016, L.P.
	By:	 	GV 2016 GP, L.P., its General Partner
	By:	 	GV 2016 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Jennifer L. Kercher

	Name:	 	Jennifer L. Kercher
	Title:	 	Authorized Signatory

  

			
	Address:	 	 Attn: Jennifer L. Kercher
 c/o GV

1600 Amphitheatre Parkway
 Mountain View, CA 94043

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

	Name:	 	Rene Russo
	Title:	 	President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms of
that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	N5 Investments AS

 
			
		
	By:	 	 /s/ Pål Jensen

			
	Pål Jensen, an authorized person, for and on
its behalf

  

			
	Address:	 	 Parkveien 55
 0256 Oslo

Norway

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

	Name:	 	Rene Russo
	Title:	 	President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms of
that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	Bill & Melinda Gates Foundation

 
			
		
	By:	 	 /s/ Jim Bromley

	Name:	 	Jim Bromley
	Title:	 	Chief Financial Officer

 
			
		
	Address:	 	1432 Elliott Ave W.

		 	Seattle, WA 98119

		 	Attn: General Counsel

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

	Name:	 	Rene Russo
	Title:	 	President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms of
that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledegment.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	SV LIFE SCIENCES FUND VI, L.P.

 
			
		
	By:	 	SV Life Sciences Fund VI (GP), L.P.,
		 	Its sole General Partner
		
	By:	 	SVLSF VI, LLC,
		 	Its sole General Partner

 
					
			
		 	By:	 	 /s/ Denise W. Marks

		 		 	 Name: Denise W. Marks
 Title: SVLSF VI, LLC,
Member

 
			
		
	Address:	 	 One Boston Place
201 Washington Street, Suite 3900
Boston, MA 02108

Attn: Denise Marks

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

	Name:	 	Rene Russo
	Title:	 	President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms of
that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	 SV LIFE SCIENCES FUND VI STRATEGIC

PARTNERS, L.P.

 
			
		
	By:    	 	SV Life Sciences Fund VI (GP), L.P.,
		 	Its sole General Partner
		
	By:    	 	SVLSF VI, LLC,
		 	Its sole General Partner

 
					
			
		 	By:	 	 /s/ Denise W. Marks

		 		 	 Name: Denise W. Marks
 Title: SVLSF VI, LLC,
Member

 
			
		
	Address:    	 	 One Boston Place
201 Washington Street, Suite 3900
Boston, MA 02108

Attn: Denise Marks

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

	Name:	 	Rene Russo
	Title:	 	President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the
terms of that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by
that certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9. 1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

													
		 	Date:                     	 		 	 /s/ Tillman U. Gerngorss
	 	
		 		 		 	Tillman U. Gerngorss	 	
							
		 		 		 	Address:	 		 	  
	 	
		 		 		 		 		 	  
	 	
		 		 		 		 		 	  
	 	

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.

			
		
	By:	 	/s/ Rene Russo

			
	Name: Rene Russo
	Title: President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on April 24, 2017, by the undersigned (the “Investor”) pursuant to the terms
of that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by that
certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”). Capitalized
terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows. 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

					
	 /s/ Michael W. Bonney

	Michael W. Bonney
			
	Address:	 		 	536 Commercial Street
		 		 	Boston, MA 02109

  

			
	Accepted and Agreed:
	
	ARSANIS, INC.

			
		
	By:	 	 /s/ Rene Russo

			
	Name: Rene Russo
	Title: President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

This Joinder Agreement is executed on September 1, 2017, by the undersigned (the “Investor”) pursuant to the
terms of that certain Second Amended and Restated Stockholders’ Agreement by and among Arsanis, Inc., a Delaware corporation (the “Company”) and certain of its Stockholders, dated as of April 12, 2016, and as amended by
that certain First Amendment to the Second Amended and Restated Stockholders’ Agreement dated as of April 24, 2017 (as so amended and as the same may be amended or amended and restated hereafter, the “Agreement”).
Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Joinder Agreement, the Investor agrees as follows: 

1.1    Acknowledgement.    Investor acknowledges that Investor is acquiring certain shares of
the capital stock of the Company (the “Stock”) as a new Investor in accordance with Section 9.1(a) of the Agreement and will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

1.2    Agreement.    Investor hereby (a) agrees that the Stock, and any other shares of
capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement, and (b) adopts the Agreement with the same force and effect as if the Investor were originally a party
thereto. 
 1.3    Notice.    Any notice required or permitted by the Agreement shall be
given to Investor at the address or facsimile number listed below the Investor’s signature hereto. 
  

			
	SECTION 32 FUND 1, LP
		
	By:	 	Section 32 GP 1, LLC
		 	its General Partner
		
	By:	 	 /s/ Jennifer L. Kercher

		 	Jennifer L. Kercher
		 	Chief Operating Officer

  

			
	ACCEPTED AND AGREED:
	
	ARANIS, INC.

			
		
	By:	 	 /s/ René Russo

			
	Name: René Russo
	Its: President and Chief Executive Officer

 —Joinder Agreement to Second Amended and Restated Stockholders’ Agreement— 

 EXHIBIT A 

SCHEDULE OF INVESTORS 
 OrbiMed Private
Investments IV, LP 
 601 Lexington Avenue (at 53rd Street) 

54th Floor 
 New York, NY 10022-4629 

Polaris Venture Partners V, L.P. 
 One Marina Park Drive, 10th
Floor 
 Boston, MA 02210 
 Polaris Venture Partners
Entrepreneurs’ Fund V, L.P. 
 [Same address as above] 

Polaris Venture Partners Founders’ Fund V, L.P. 
 [Same
address as above] 
 Polaris Venture Partners Special Founders’ Fund V, L.P. 

[Same address as above] 
 SV Life Sciences Fund V, L.P. 

One Boston Place 
 201 Washington Street, Suite 3900 

Boston, MA 02108 
 Attn: Denise Marks 

SV Life Sciences Fund V Strategic Partners, L.P. 
 [Same address
as above] 
 SV Life Sciences Fund VI, L.P. 
 [Same address as
above] 
 SV Life Sciences Fund VI Strategic Partners, L.P. 

[Same address as above] 
 NeoMed Innovation V L.P. 

13, Castle Street 
 Jersey, JE4 5UT 

cc to: claudio@neomed.net 
 EMBL Technology Fund II
GmbH & Co. KG 
 Boxbergring 107 
 D-69126 Heidelberg 
 Germany 

Attn: Jan Adams 

  
 1 

 Anna-Maria and Stephen Kellen Foundation, Inc. 

1345 Avenue of the Americas, 48th Floor 

New York, NY 10105-0048 
 Attn. Michael M. Kellen 

Bill & Melinda Gates Foundation 
 Address: 

For UPS, FedEx, DHL: 

Bill & Melinda Gates Foundation 

1432 Elliott Ave West 
 Seattle,
WA 98119 
 For United States Postal Service 

Bill & Melinda Gates Foundation 

PO Box 23350 
 Seattle, WA 98102

 For Messengers & Courier Service 

Bill & Melinda Gates Foundation 

ATTN: Loading Dock 
 500 Fifth Ave
N 
 Seattle, WA 98109-4636 

Fax No. 206.497.7100 
 Attn:
Jim Bromley, Chief Financial Officer 
 With a copy (which shall not constitute notice): 

Andrew Farnum, Director Program-Related Investments 

With a copy (which shall not constitute notice): 

Claire White 
 K&L Gates LLP

 925 4th Ave, Suite 2900 

Seattle WA, 98104 
 GV 2016, L.P. 

Email: notice@gv.com 
 Attn: Jennifer L. Kercher 

c/o GV 
 1600 Amphitheatre Parkway 

Mountain View, CA 94043 
 Alexandria Venture Investments, LLC

 385 E. Colorado Blvd., Suite 299 
 Pasadena, CA 91101 

  
 2 

 Michael W. Bonney 

536 Commercial Street 
 Boston, MA 02109 

N5 Investments AS 
 Parkveien 55 

0256 Oslo 
 Norway 

Tillman U. Gerngross 
 Section 32 Fund 1, LP 

2033 San Elijo Avenue #565 
 Cardiff by the Sea, CA 92007 

  
 3 

 

ARSANIS, INC. 
 FIRST AMENDMENT 

TO THE 
 SECOND AMENDED
AND RESTATED 
 STOCKHOLDERS’ AGREEMENT 

This FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Amendment”) is entered into as of
April 24, 2017, by and among Arsanis, Inc. (the “Company”), the existing investors listed on the signature pages hereto under the heading “Investors” (the “Existing Investors”), the individuals listed
on the signature pages hereto under the heading “Founders” (the “Founders”), and the individuals listed on the signature pages hereto under the heading “Restricted Stockholders” (the “Restricted
Stockholders”). Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Stockholders Agreement (each as defined below). 

RECITALS 

WHEREAS, the Existing Investors are holders of the Company’s Series A Preferred Stock, Series B Preferred Stock and/or Series C Preferred
Stock; 
 WHEREAS, the Company, the Existing Investors, the Founders and the Restricted Stockholders are parties to a Second Amended
and Restated Stockholders’ Agreement dated as of April 12, 2016 (the “Stockholders Agreement”); 
 WHEREAS, the
Company proposes to issue and sell shares of its Series D Convertible Preferred Stock, $0.001 par value per share (the “Series D Preferred Stock”), pursuant to the Series D Preferred Stock Purchase Agreement (the “Purchase
Agreement”) of even date herewith, to be entered into by the Company, the Existing Investors and certain new investors; 
 WHEREAS,
the Company, the Existing Investors, the Founders and the Restricted Stockholders wish to amend the Stockholders Agreement to, among other things, clarify that the Series D Preferred Stock shall be “Preferred Stock” as defined in the
preamble to the Stockholders Agreement; 
 WHEREAS, pursuant to Section 9.8 of the Stockholders Agreement, the Stockholders Agreement
may be amended with the written consent of (i) the Company and (ii) the Stockholders holding at least a majority of the Shares held by all Stockholders voting on as-converted to Common Stock basis
(the “Required Holders”); 
 WHEREAS, the undersigned Existing Investors, Founders and Restricted Stockholders constitute
the Required Holders; and 
 WHEREAS, the parties intend that these recitals be a part of the Stockholders Agreement, as amended by this
Amendment. 

 NOW, THEREFORE, in consideration of the mutual agreements, covenants and considerations contained
herein, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1.    Amendments to the Stockholders Agreement. 

1.1    Definitions. The Stockholders Agreement is hereby amended so that the defined term “Preferred
Stock” set forth therein (or herein) shall include the Series D Preferred Stock for all purposes thereunder (or hereunder), all terms defined in this Amendment shall apply as if set forth in full in the Stockholders Agreement, and in the event
of any conflict between a term defined in the Stockholders Agreement and this Amendment, the meaning set forth in this Amendment shall control. 

1.2    Exceptions to Drag-Along Rights. The Stockholders Agreement is hereby amended so that the following
provisions are added to Section 2.3 at the end thereof as follows: 
 “(f)    any covenants that any Investor
shall be required to make (other than in relation to such Investor’s indemnification obligations) in connection with a Proposed Sale shall be limited to reasonable covenants regarding confidentiality, publicity, and similar matters; 

(g)    the Bill & Melinda Gates Foundation shall not be required to amend, extend or terminate any contractual or
other relationship with the Company, the acquirer, or their respective affiliates (including without limitation, that certain Letter Agreement, dated on or about April , 2017, between the Company and the Bill & Melinda Gates Foundation, and
any grant agreement from the Bill & Melinda Gates Foundation then currently in effect); except the Stockholders’ Agreement or that certain Second Amended and Restated Investors’ Rights Agreement, as amended, to the extent such
agreements (or any specific provisions therein) terminate by their terms in connection with a Proposed Sale; 
 (h)
    no Investor shall be required to agree to any covenant not to compete or covenant not to solicit customers, employees, or suppliers of any party unless such Investor is an employee, consultant, or similar service provider to
the Company at the time of the closing of the Proposed Sale.” 
 1.3    Termination. The Stockholders
Agreement is hereby amended such that the dollar amount “$28.95” as it appears in Section 5.1(b) thereof is hereby deleted and replaced with the dollar amount “$9.83.” 

1.4    Transfer of Rights. The Stockholders Agreement is hereby amended so that the first sentence of
Section 6 is replaced in its entirety to read as follows: 
 “This Agreement, and the rights and obligations of each Investor
hereunder, may be assigned by such Investor (a) to any person or entity to which such Investor transfers a number of shares of Preferred Stock equal to not less than five percent (5%) of the total number of shares of Preferred Stock held by
such Investor 

 
(subject to adjustment for any stock dividend, stock split, stock split-up, combination or shares or the like) immediately following the Closing (as
defined in the Purchase Agreement), (b) if the Investor is an individual, to any family member or trust or partnership established for such family member, (c) if the Investor is a corporation, partnership, limited liability company or other
entity, to any current or former partner (including general partner and limited partner), shareholder, member, or other affiliate of the Investor or (d) in the case of the Bill & Melinda Gates Foundation, to a charitable trust or other
entity a majority of the trustees of which are also trustees of the Bill & Melinda Gates Foundation.” 

1.5    Stand-Off Agreement. Section 8 of the Stockholders Agreement is hereby amended by adding the following
paragraph after Section 8(c): 
 “Notwithstanding the foregoing, with respect to the Investors, to the extent that the provisions
of this Section 8 are in conflict with the “stand-off” agreement provisions in the Second Amended and Restated Investors’ Rights Agreement, dated as of April 12, 2016, and as amended
from time to time (the “Rights Agreement”), the provisions in the Rights Agreement shall control.” 

1.6    Complete Agreement; Amendments. The Stockholders Agreement is hereby amended such that a new sentence is
added to Section 9.8(b) at the end thereof as follows: 
 “Notwithstanding the foregoing, Subsections 2.3(f) through 2.3(h) may not
be amended or waived without the written consent of the Bill & Melinda Gates Foundation.” 

1.7    Exhibit A. Each individual and entity listed on Exhibit A attached hereto is hereby added to Exhibit A of
the Stockholders Agreement, subject to the execution by such individual or entity of a counterpart signature page to the Stockholders Agreement, as amended by this Amendment, agreeing to be bound by and subject to the terms of the Stockholders
Agreement as so amended as an Investor and a Stockholder thereunder, and the term “Investors” thereunder and hereunder shall include such individuals and entities. 

2.    No Further Amendment. The Stockholders Agreement, as amended by this Amendment, is hereby ratified and
confirmed in all respects, shall continue in full force and effect and shall, together with this Amendment, be read and construed as a single agreement. 

3.    Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of all of the parties
to the Stockholders Agreement, their successors and assigns, heirs, devisees, legates and personal representatives. 

4.    Counterparts. This Amendment may be executed in multiple counterparts, each of which shall be deemed an
original for all purposes and all of which shall be deemed collectively to be one agreement. 

 5.    Governing Law. This Amendment shall be governed by and construed
under the laws of the State of Delaware as applied to agreements among Delaware residents entered into and to be performed entirely within Delaware. 

[Remainder of page intentionally left blank.] 

 IN WITNESS WHEREOF, the
parties hereto have executed this First Amendment to the Second Amended and Restated Stockholders’ Agreement as of the date set forth in the first paragraph hereof. 

 

			
	COMPANY:
	
	ARSANIS, INC.
		
	By:	 	 /s/ Rene Russo

		 	Name: Rene Russo
		 	Title:   President

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

  

	
	FOUNDERS:
	
	 /s/ Eszter Nagy

	Eszter Nagy
	  
 /s/ Tillman U.
Gerngross

	Tillman U. Gerngross
	  
 /s/ Errik B. Anderson

	Errik B. Anderson

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
	
	RESTRICTED STOCKHOLDERS:
	
	 /s/ Gabor
Nagy                Apr 20, 2017

	Gabor Nagy
	  
 /s/ Zoltan Magyarics

	Zoltan Magyarics

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
			
	INVESTORS:
	
	ORBIMED PRIVATE INVESTMENTS IV LP
		
	By:	 	OrbiMed Capital GP IV LLC
		 	Its General Partner
		
	By:	 	OrbiMed Advisors LLC,
		 	Its Managing Member

  

							
		 		 	By:	 	 /s/ Carl L. Gordon

		 		 		 	Name: Carl L. Gordon
		 		 		 	Title: Member

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
			
	INVESTORS:
	
	POLARIS VENTURE PARTNERS V, L.P.
		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner

  

							
		 		 	By:	 	 /s/ Max Eisenberg

		 		 		 	Name: Max Eisenberg
		 		 		 	Title: Attorney-in-fact

  

			
	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND V, L.P.
		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner

  

							
		 		 	By:	 	 /s/ Max Eisenberg

		 		 		 	Name: Max Eisenberg
		 		 		 	Title: Attorney-in-fact

  

			
	 POLARIS VENTURE PARTNERS FOUNDERS’

FUND, V, L.P.

		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner

  

							
		 		 	By:	 	 /s/ Max Eisenberg

		 		 		 	Name: Max Eisenberg
		 		 		 	Title: Attorney-in-fact

  

			
	 POLARIS VENTURE PARTNERS SPECIAL

FOUNDERS’ FUND V, L.P.

		
	By:	 	Polaris Venture Management Co. V, L.L.C.,
		 	Its General Partner

  

							
		 		 	By:	 	 /s/ Max Eisenberg

		 		 		 	Name: Max Eisenberg
		 		 		 	Title: Attorney-in-fact

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
			
	INVESTORS:
	
	SV LIFE SCIENCES FUND V, L.P.
		
	By:	 	SV Life Sciences Fund V (GP), L.P.,
		 	Its sole General Partner
		
	By:	 	SVLSF V, LLC,
		 	Its sole General Partner

  

							
		 		 	By:	 	 /s/ Denise W. Marks

		 		 		 	Name: Denis W. Marks
		 		 		 	Title: SVLSF V, LLC, Member

  

			
	SV LIFE SCIENCES FUND V STRATEGIC PARTNERS, L.P.
		
	By:	 	SV Life Sciences Fund V (GP), L.P.,
		 	Its sole General Partner
		
	By:	 	SVLSF V, LLC,
		 	Its sole General Partner

  

							
		 		 	By:	 	 /s/ Denise W. Marks

		 		 		 	Name: Denis W. Marks
		 		 		 	Title: SVLSF V, LLC, Member

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
					
	INVESTORS:
	
	NEOMED INNOVATION V L.P.
			
	By:	 	/s/ TAMARA WILLIAMS        	 	/s/ JAMES KEATING
		 	Name: TAMARA WILLIAMS        	 	JAMES KEATING
		 	Title: DIRECTOR	 	DIRECTOR
	  
 ACTING BY ITS GENERAL PARTNER

NEOMEO INNOVATION V LIMITED

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
			
	INVESTORS:
	
	EMBL TECHNOLOGY FUND II GMBH & CO. KG
		
	By:	 	EMBL VENTURES VERWALTUNGS GMBH,
		 	 its General Partner

  

			
	By:	 	 /s/ Jan Adams

		 	Name: Jan Adams
		 	Title:   Executive Director

  

			
	By:	 	 /s/ Dr. Stefan Herr

		 	Name: Stefan Herr
		 	Title:   Executive Director

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 
			
	INVESTORS:
	
	Anna-Maria and Stephen Kellen Foundation, Inc.

 
			
		
	By:	 	/s/ Michael M. Kellen

 
			
	Name: Michael M. Kellen
	Title: President

 Signature Page to First Amendment to Second Amended and Restated Stockholders’ Agreement 

 EXHIBIT A 

Bill & Melinda Gates Foundation 
 Address: 

For UPS, FedEx, DHL: 

Bill & Melinda Gates Foundation 

1432 Elliott Ave West 
 Seattle,
WA 98119 
 For United States Postal Service 

Bill & Melinda Gates Foundation 

PO Box 23350 
 Seattle, WA 98102

 For Messengers & Courier Service 

Bill & Melinda Gates Foundation 

ATTN: Loading Dock 
 500 Fifth Ave
N 
 Seattle, WA 98109-4636 

Fax No. 206.497.7100 
 Attn:
Jim Bromley, Chief Financial Officer 
 With a copy (which shall not constitute notice): 

Andrew Farnum, Director Program-Related Investments 

With a copy (which shall not constitute notice): 

Claire White 
 K&L Gates LLP

 925 4th Ave, Suite 2900 

Seattle WA, 98104 
 GV 2016, L.P. 

Email: notice@gv.com 
 Attn: Jennifer L. Kercher 

c/o GV 
 1600 Amphitheatre Parkway 

Mountain View, CA 94043 
 Alexandria Venture Investments, LLC

 385 E. Colorado Blvd., Suite 299 
 Pasadena, CA 91101 

Michael W. Bonney 
 536 Commercial Street 

Boston, MA 02109 

 N5 Investments AS 

Parkveien 55 
 0256 Oslo 

Norway 
 SV Life Sciences Fund VI, L.P. 

One Boston Place 
 201 Washington Street, Suite 3900 

Boston, MA 02108 
 Attn: Denise Marks 

SV Life Sciences Fund VI Strategic Partners, L.P. 
 One Boston
Place 
 201 Washington Street, Suite 3900 
 Boston, MA 02108

 Attn: Denise Marks 
 Tillman U. GerngrossEX-4.1

 Exhibit 4.1 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT OR A SALE IN COMPLIANCE WITH RULE
144 UNDER THE ACT. 
 PRECIPIO, INC. 

WARRANT TO PURCHASE [            ] SHARES OF COMMON STOCK 

Warrant No.: 2017-[        ] 

Date of Issuance: October [    ], 2017 

VOID AFTER October [    ], 2022 

THIS CERTIFIES THAT, for value received,
[        ], or permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Precipio, Inc., a Delaware corporation
(the “Company”), up to [        ] shares of the common stock of the Company, par value $7.50 per share (the “Common Stock”). This warrant is one of a series of warrants
issued by the Company as of the date hereof (individually a “Warrant”; collectively, “Company Warrants”) pursuant to those certain settlement agreements between the Company and each of the Holders, each dated as of
October, [    ], 2017 (each, a “Settlement Agreement”). 
 1. Definitions. Capitalized
terms used herein but not otherwise defined herein shall have their respective meanings as set forth in the Settlement Agreement. As used herein, the following terms shall have the following respective meanings: 

(A) “Eligible Market” means any of the New York Stock Exchange, the NYSE Amex, The NASDAQ Global Market, The NASDAQ Global
Select Market or The NASDAQ Capital Market. 
 (B) “Exercise Period” shall mean the period ending five years from the date
hereof, unless sooner terminated as provided below. 
 (C) “Exercise Price” shall mean $7.50 per share, subject to
adjustment pursuant to Section 4 below. 
 (D) “Exercise Shares” shall mean the shares of Common Stock
issuable upon exercise of this Warrant. 
 (E) “Fundamental Transaction” means that the Company shall, directly or
indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of all or
substantially all of the properties or assets of the Company to another Person, or (iii) enter into an agreement with another Person pursuant to 

  
 1 

 
which such Person agrees to make a purchase, tender or exchange offer that is accepted by the holders of more than the 50% of the outstanding shares of Common Stock (not including any shares of
Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (iv) consummate a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other
business combination), (v) reorganize, recapitalize or reclassify its Common Stock, or (vi) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall
become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding
Common Stock. 
 (F) “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable
Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the
date of consummation of the Fundamental Transaction. 
 (G) “Person” means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. 

(H) “Successor Entity” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or
surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. 

(I) “Trading Day” shall mean (a) any day on which the Common Stock is listed or quoted and traded on its primary
Trading Market, (b) if the Common Stock is not then listed or quoted and traded on any Eligible Market, then a day on which trading occurs on the OTC Bulletin Board (or any successor thereto), or (c) if trading does not occur on the OTC
Bulletin Board (or any successor thereto), any Business Day. 
 (J) “Trading Market” shall mean the OTC Bulletin Board or
any other Eligible Market, or any national securities exchange, market or trading or quotation facility on which the Common Stock is then listed or quoted. 

2. Exercise of Warrant. 

2.1 Exercise. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by
delivery of the following to the Company at its address set forth on the signature page hereto (or at such other address as it may designate by notice in writing to the Holder): 

(A) An executed Notice of Exercise in the form attached hereto; 

  
 2 

 (B) Payment of the Exercise Price either (i) in cash or by check or (ii) pursuant to
Section 2.2 below; and 
 (C) This Warrant. 

Execution and delivery of the Notice of Exercise shall have the same effect as cancellation of the original Warrant and issuance of a new
Warrant evidencing the right to purchase the remaining number of Exercise Shares, if any. 
 Certificates for shares purchased hereunder
shall be transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder’s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission system if the Company is a
participant in such system, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise within three business days from the delivery to the Company of the Notice of Exercise, surrender of this Warrant and
payment of the aggregate Exercise Price as set forth above. This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to
have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such
surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are
open. 
 Subject to the final sentence of this paragraph and to the extent permitted by law, the Company’s obligations to issue and
deliver Exercise Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any
judgment against any person or entity or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person or entity of any obligation to the Company
or any violation or alleged violation of law by the Holder or any other person or entity, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Exercise
Shares. The Holder shall, subject to the following proviso, have the right to pursue any remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to
the Company’s failure to timely deliver Exercise Shares upon exercise of this Warrant as required pursuant to the terms hereof; provided, however, that notwithstanding anything to the contrary in this Warrant or in the Settlement
Agreements, if the Company is for any reason unable to deliver Exercise Shares upon exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to pay to the Holder any cash or other consideration or
otherwise “net cash settle” this Warrant. 
 Except for cash in lieu of fractional shares as provided in Section 5,
this Warrant may not be settled by the Company for cash to the Holder in lieu of Common Stock. 

  
 3 

 2.2 Net Exercise. If during the Exercise Period the fair market value of one share of the
Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash or by check, the Holder may, at its election, effect a “net exercise” of this Warrant,
in which event, if so effected, the Holder shall receive Exercise Shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company, together
with the properly endorsed Notice of Exercise, in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula: 
  

			
	X =	  	Y (A – B)
	  	A

 Where: 
 X = the
number of Exercise Shares to be issued to the Holder; 
 Y = the number of Exercise Shares with respect to which this Warrant is being
exercised; 
 A = the Fair Market Value (as defined below) of one share of the Company’s Common Stock (at the date of such calculation);
and 
 B = Exercise Price (as adjusted to the date of such calculation). 

For purposes of this Warrant, the “Fair Market Value” of one share of Common Stock shall mean (i) the average of the closing sales
prices for the shares of Common Stock on The NASDAQ Global Market or other Eligible Market where the Common Stock is listed or traded as reported by Bloomberg Financial Markets (or a comparable reporting service of national reputation selected by
the Company and reasonably acceptable to the Holder if Bloomberg Financial Markets is not then reporting sales prices of such security) (collectively, “Bloomberg”) for the ten (10) consecutive trading days immediately prior to
the Exercise Date, or (ii) if an Eligible Market is not the principal Trading Market for the shares of Common Stock, the average of the reported sales prices reported by Bloomberg on the principal Trading Market for the Common Stock during the
same period, or, if there is no sales price for such period, the last sales price reported by Bloomberg for such period, or (iii) if neither of the foregoing applies, the last sales price of such security in the
over-the-counter market on the pink sheets or bulletin board for such security as reported by Bloomberg, or if no sales price is so reported for such security, the last
bid price of such security as reported by Bloomberg or (iv) if fair market value cannot be calculated as of such date on any of the foregoing bases, the fair market value shall be as determined by the Board of Directors of the Company in the
exercise of its good faith judgment. 
 2.3 Issuance Of New Warrants. Upon any partial exercise of this Warrant, the Company, at its
expense, will forthwith and, in any event within five business days, issue and deliver to the Holder a new warrant or warrants of like tenor, registered in the name of the Holder, exercisable, in the aggregate, for the balance of the number of
shares of Common Stock remaining available for purchase under this Warrant. 

  
 4 

 2.4 Payment Of Taxes And Expenses. The Company shall pay any recording, filing, stamp or
similar tax which may be payable in respect of any transfer involved in the issuance of, and the preparation and delivery of certificates (if applicable) representing, (i) any Exercise Shares purchased upon exercise of this Warrant and/or
(ii) new or replacement warrants in the Holder’s name or the name of any transferee of all or any portion of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any
transfer involved in the issuance, delivery or registration of any certificates for Exercise Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of
holding or transferring this Warrant or receiving Exercise Shares upon exercise hereof. 
 3. Covenants of the Company. 

3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of
the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees
that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any
time during the Exercise Period the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will use its commercially reasonable efforts to take such corporate action in
compliance with applicable law as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. 

3.2 Notices of Record Date and Certain Other Events. In the event of any taking by the Company of a record of the holders of any class
of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at least fifteen (15) days prior to the date on which any such record is to
be taken for the purpose of such dividend or distribution, a notice specifying such date. In the event of any voluntary dissolution, liquidation or winding up of the Company, the Company shall mail to the Holder, at least fifteen (15) days
prior to the date of the occurrence of any such event, a notice specifying such date. In the event the Company authorizes or approves, enters into any agreement contemplating, or solicits stockholder approval for any Fundamental Transaction, as
defined in Section 6 herein, the Company shall mail to the Holder, at least fifteen (15) days prior to the date of the closing of such event, a notice specifying such date. Notwithstanding the foregoing, the failure to deliver such notice
or any defect therein shall not affect the validity of the corporate action required to be described in such notice. 
 4. Adjustment of
Exercise Price and Shares. The Exercise Price and number of Exercise Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 4. 

  
 5 

 (A) If the Company, at any time while this Warrant is outstanding, (i) pays a stock
dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines
outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such
event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or
combination. 
 (B) If the Company, at any time while this Warrant is outstanding, distributes to holders of Common Stock
(i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset (in
each case, “Distributed Property”), then in each such case the Holder shall be entitled upon exercise of this Warrant for the purchase of any or all of the Exercise Shares, to receive the amount of Distributed Property which would
have been payable to the Holder had such Holder been the holder of such Exercise Shares on the record date for the determination of stockholders entitled to such Distributed Property. The Company will at all times set aside in escrow and keep
available for distribution to such holder upon exercise of this Warrant a portion of the Distributed Property to satisfy the distribution to which such Holder is entitled pursuant to the preceding sentence. 

(C) Upon the occurrence of each adjustment pursuant to this Section 4, the Company at its expense will, at the written request of
the Holder, promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Exercise Shares or
other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly
deliver a copy of each such certificate to the Holder and to the Company’s transfer agent. 
 5. Fractional Shares. No
fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share (a) the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market value of an Exercise Share by such fraction and (b) the number of Exercise Shares to be issued will be rounded down
to the nearest whole share. 

  
 6 

 6. Fundamental Transactions. This Warrant shall terminate upon a Fundamental Transaction.
The Company shall provide written notice to the Holder of a Fundamental Transaction at least ten days prior to the consummation thereof. Such notice shall contain the terms of such Fundamental Transaction. 

7. No Stockholder Rights. Other than as provided in Section 3.2 or otherwise herein, this Warrant in and of itself shall
not entitle the Holder to any voting rights or other rights as a stockholder of the Company. 
 8. Transfer of Warrant. Subject to
applicable laws and any restrictions on transfer set forth in the Settlement Agreement, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of
assignment attached hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company and its counsel. Any purported transfer of all or any portion of this
Warrant in violation of the provisions of this Warrant shall be null and void. 
 9. Lost, Stolen, Mutilated or Destroyed Warrant. If
this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of
like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant
shall be at any time enforceable by anyone. 
 10. Notices, Etc. All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed facsimile to the facsimile number specified in writing by the recipient or by email if sent during normal business hours
of the recipient on a Trading Day, if not, then on the next Trading Day, (c) the next Trading Day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the Company at the address listed on the signature page hereto and to Holder at the applicable address set forth on the applicable signature page to the Settlement Agreement or at such other address as the Company or
Holder may designate by ten (10) days advance written notice to the other parties hereto. 
 11. Acceptance. Receipt of this
Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 
 12. Governing
Law. This Warrant and all rights, obligations and liabilities hereunder shall be governed by, and construed in accordance with, the internal laws of the State of California, without giving effect to the principles of conflicts of law that would
require the application of the laws of any other jurisdiction. 

  
 7 

 13. Amendment or Waiver. Any term of this Warrant may be amended or waived (either
generally or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the Holder. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to
be, or construed as, a further or continuing waiver of any such term, condition or provision. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK] 

  
 8 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of the Date of Issuance set out above. 
  

			
	PRECIPIO, INC.
		
	By:	 	 
		 	Name: Ilan Danieli
		 	Title: President and Chief Executive Officer

 SIGNATURE PAGE TO 

WARRANT 

 NOTICE OF EXERCISE 

TO: PRECIPIO, INC. 
 (1) The undersigned
hereby elects to purchase          shares of the common stock, par value $0.01 the “Common Stock”), of Precipio, Inc. (the “Company”) pursuant to the terms of the attached
Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

[    ] The undersigned hereby elects to purchase          shares of Common
Stock of the Company pursuant to the terms of the net exercise provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2) Please issue the certificate for shares of Common Stock in the name of: 

 

					
	 Name:

SS# or EIN:
 Street Address:

City, State Zip Code:
	  		  	

 (3) If such number of shares shall not be all the shares purchasable upon the exercise of the Warrants
evidenced by this Warrant, a new warrant certificate for the balance of such Warrants remaining unexercised shall be registered in the name of and delivered to: 
  

					
	 Name:

SS# or EIN:
 Street Address:

City, State Zip Code:
	  		  	

 Dated: 
  

	
	
	   

	(Signature)
	
	   

	(Print name)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]